Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Prokidney (PROK) over the last 4 years, with Q3 2025 value amounting to $95.3 million.

  • Prokidney's Cash & Equivalents fell 1180.98% to $95.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.3 million, marking a year-over-year decrease of 1180.98%. This contributed to the annual value of $99.1 million for FY2024, which is 6343.22% up from last year.
  • Per Prokidney's latest filing, its Cash & Equivalents stood at $95.3 million for Q3 2025, which was down 1180.98% from $84.9 million recorded in Q2 2025.
  • Prokidney's 5-year Cash & Equivalents high stood at $506.3 million for Q3 2022, and its period low was $60.6 million during Q4 2023.
  • Over the past 4 years, Prokidney's median Cash & Equivalents value was $108.1 million (recorded in 2024), while the average stood at $196.0 million.
  • In the last 5 years, Prokidney's Cash & Equivalents tumbled by 8762.9% in 2023 and then surged by 6343.22% in 2024.
  • Over the past 4 years, Prokidney's Cash & Equivalents (Quarter) stood at $490.3 million in 2022, then crashed by 87.63% to $60.6 million in 2023, then surged by 63.43% to $99.1 million in 2024, then fell by 3.83% to $95.3 million in 2025.
  • Its Cash & Equivalents stands at $95.3 million for Q3 2025, versus $84.9 million for Q2 2025 and $97.8 million for Q1 2025.